Prospects of Replication-Deficient Adenovirus Based Vaccine Development Against SARS-CoV-2

Overview

Journal Vaccines (Basel)

Date 2020 Jun 14

PMID 32531955

Citations 10

Authors

Mariangela Garofalo

Monika Staniszewska

Stefano Salmaso

Paolo Caliceti

Katarzyna Wanda Pancer

Magdalena Wieczorek

Lukasz Kuryk

Affiliations

Soon will be listed here.

Abstract

The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency. The serious outbreak position is affecting people worldwide and requires rapid measures to be taken by healthcare systems and governments. Vaccinations represent the most effective strategy to prevent the epidemic of the virus and to further reduce morbidity and mortality with long-lasting effects. Nevertheless, currently there are no licensed vaccines for the novel coronaviruses. Researchers and clinicians from all over the world are advancing the development of a vaccine against novel human SARS-CoV-2 using various approaches. Herein, we aim to present and discuss the progress and prospects in the field of vaccine research towards SARS-CoV-2 using adenovirus (AdV) replication deficient-based strategies, with a comprehension that may support research and combat this recent world health emergency.

Citing Articles

Induction of an immune response by a nonreplicating adenoviruses-based formulation versus a commercial pseudo-SARS-CoV-2 vaccine.

Baran J, Kuryk L, Garofalo M, Pancer K, Wieczorek M, Kazek M BioTechnologia (Pozn). 2024; 105(3):263-272.

PMID: 39439719 PMC: 11492889. DOI: 10.5114/bta.2024.141805.

Stability of Neutralizing Antibody of PastoCoAd Vaccine Candidates against a Variant of Concern of SARS-CoV-2 in Animal Models.

Panahi M, Teimoori A, Esmaeili S, Aminianfar H, Milani A, Hosseini S Iran Biomed J. 2024; 28(4):214-20.

PMID: 39044638 PMC: 11444480. DOI: 10.61186/ibj.3980.

Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models.

Kuryk L, Moller A Mol Ther Oncolytics. 2023; 28:158-170.

PMID: 36816748 PMC: 9922816. DOI: 10.1016/j.omto.2023.01.002.

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic.

Mendonca S, Lorincz R, Boucher P, Curiel D NPJ Vaccines. 2021; 6(1):97.

PMID: 34354082 PMC: 8342436. DOI: 10.1038/s41541-021-00356-x.

Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells.

Garofalo M, Bellato F, Magliocca S, Malfanti A, Kuryk L, Rinner B Pharmaceutics. 2021; 13(7).

PMID: 34202714 PMC: 8309094. DOI: 10.3390/pharmaceutics13070949.

References

Klugman K, Black S . Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proc Natl Acad Sci U S A. 2018; 115(51):12896-12901. PMC: 6304973. DOI: 10.1073/pnas.1721095115. View

Kim D, Lee J, Yang J, Kim J, Kim V, Chang H . The Architecture of SARS-CoV-2 Transcriptome. Cell. 2020; 181(4):914-921.e10. PMC: 7179501. DOI: 10.1016/j.cell.2020.04.011. View

Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S . The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7(3):226-36. PMC: 2750777. DOI: 10.1038/nrmicro2090. View

Palmu A, Jokinen J, Nieminen H, Rinta-Kokko H, Ruokokoski E, Puumalainen T . Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis. 2013; 14(3):205-12. DOI: 10.1016/S1473-3099(13)70338-4. View

Crenshaw B, Jones L, Bell C, Kumar S, Matthews Q . Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy. Biomedicines. 2019; 7(3). PMC: 6784011. DOI: 10.3390/biomedicines7030061. View

Garofalo M, Villa A, Crescenti D, Marzagalli M, Kuryk L, Limonta P . Heterologous and cross-species tropism of cancer-derived extracellular vesicles. Theranostics. 2019; 9(19):5681-5693. PMC: 6735396. DOI: 10.7150/thno.34824. View

Lucchese G . Epitopes for a 2019-nCoV vaccine. Cell Mol Immunol. 2020; 17(5):539-540. PMC: 7091830. DOI: 10.1038/s41423-020-0377-z. View

Coutard B, Valle C, de Lamballerie X, Canard B, Seidah N, Decroly E . The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020; 176:104742. PMC: 7114094. DOI: 10.1016/j.antiviral.2020.104742. View

Kuryk L, Moller A, Vuolanto A, Pesonen S, Garofalo M, Cerullo V . Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks. Int J Mol Sci. 2019; 20(3). PMC: 6387112. DOI: 10.3390/ijms20030621. View

10.

Chan J, Yuan S, Kok K, To K, Chu H, Yang J . A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395(10223):514-523. PMC: 7159286. DOI: 10.1016/S0140-6736(20)30154-9. View

11.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

12.

Clerici M, Tacket C, Via C, Lucey D, Muluk S, Zajac R . Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur J Immunol. 1991; 21(6):1345-9. DOI: 10.1002/eji.1830210603. View

13.

Kuryk L, Moller A . Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. J Med Virol. 2020; 92(8):1309-1315. PMC: 7496614. DOI: 10.1002/jmv.25677. View

14.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

15.

Lauer K, Borrow R, Blanchard T . Multivalent and Multipathogen Viral Vector Vaccines. Clin Vaccine Immunol. 2016; 24(1). PMC: 5216423. DOI: 10.1128/CVI.00298-16. View

16.

Kuryk L, Moller A, Jaderberg M . Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019; 8(2):e1532763. PMC: 6343802. DOI: 10.1080/2162402X.2018.1532763. View

17.

Spiering M . Primer on the Immune System. Alcohol Res. 2015; 37(2):171-5. PMC: 4590614. View

18.

Wold W, Toth K . Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013; 13(6):421-33. PMC: 4507798. DOI: 10.2174/1566523213666131125095046. View

19.

Negro F . Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?. Swiss Med Wkly. 2020; 150:w20249. DOI: 10.4414/smw.2020.20249. View

20.

Barouch D, Pau M, Custers J, Koudstaal W, Kostense S, Havenga M . Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004; 172(10):6290-7. DOI: 10.4049/jimmunol.172.10.6290. View